Boston Scientific (GB:0HOY)
NYSE:0HOY
0HOY Stock Chart & Stats
$61.45
$4.57(4.95%)
At close: 4:00 PM EST
$61.45
$4.57(4.95%)
Day’s Range― - ―
52-Week Range$60.64 - $109.51
Previous CloseN/A
Volume17.35K
Average Volume (3M)12.12K
Market Cap
$91.83B
Enterprise Value$102.20B
Total Cash (Recent Filing)$2.04B
Total Debt (Recent Filing)$12.42B
Price to Earnings (P/E)48.9
Beta0.59
Next Earnings
Apr 22, 2026EPS Estimate
0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.80
Shares Outstanding1,486,175,200
10 Day Avg. Volume12,362
30 Day Avg. Volume12,119
Financial Highlights & Ratios
PEG Ratio0.88
Price to Book (P/B)5.82
Price to Sales (P/S)7.03
P/FCF Ratio38.59
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue5.09
Enterprise Value/Gross Profit7.38
Enterprise Value/Ebitda20.82
Forecast
1Y Price Target
$103.00Price Target Upside67.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering26
EPS Forecast (FY)3.46
Revenue Forecast (FY)$22.25B
Bulls Say, Bears Say
Bulls Say
Clinical Trial Efficacy And SafetyCHAMPION-AF met primary efficacy and safety endpoints, showing the device matched anticoagulants for major events while reducing clinically relevant bleeding, which supports broader clinical adoption of left atrial appendage closure.
Physician Adoption And Market DevelopmentKey opinion leader feedback combined with presentations at major cardiology conferences boosted clinician confidence in the device, which can accelerate procedure volumes and payer awareness.
Regulatory And Reimbursement ExpansionRegulatory agencies and reimbursement authorities appear positioned to broaden the device's label and coverage, which could open the therapy to a wider patient population and improve market penetration.
Bears Say
Analyst Forecasts And Earnings SensitivityAnalysts lowered estimates to reflect slower trends in U.S. electrophysiology procedures and the Watchman product line, raising the stock's sensitivity to earnings and sell‑side forecast revisions.
Competitive Pressure And Conflicting DataPublication of competing CLOSURE data together with rising alternative devices could create clinician confusion and slow adoption of the Watchman franchise in key markets.
Ischemic Stroke Safety ConcernMarket focus on a small excess of ischemic strokes in the device arm versus anticoagulants has pressured the WATCHMAN FLX franchise and increased clinician skepticism about stroke equivalence.
Boston Scientific News
0HOY FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest share price was $60.64 and its highest was $109.51 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $91.83B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Apr 22, 2026 which is in 11 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Feb 04, 2026. The company reported $0.8 earnings per share for the quarter, beating the consensus estimate of $0.781 by $0.019.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Boston Scientific dividends here
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.79.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,486,175,200 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.8 in its last earnings report, beating expectations of $0.781. Following the earnings report the stock price went down -14.612%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in GB:0HOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$103.00 (67.62% Upside)
$103.00 (67.62% Upside)
Blogger Sentiment
Bullish
GB:0HOY Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.30%
12-Months-Change
Fundamentals
Return on Equity
12.53%
Trailing 12-Months
Asset Growth
10.86%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
0HOY Company Deck
0HOY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized materially strong financial performance in 2025 (record revenues >$20B, double-digit organic growth, EPS and margin expansion, and robust free cash flow) with multiple high-growth franchises (EP, WATCHMAN, IO, cardiovascular) and confident 2026 guidance and long-range targets. Challenges were acknowledged — AXIOS product removal affecting Endo H1, ACURATE discontinuation impacting EMEA and Q1, underperformance in urology, a meaningful GAAP litigation charge, and competitive share dynamics in EP — but management provided mitigation paths and timing for resolution (midyear fixes, product launches, tuck-in M&A). Overall, positives (broad-based growth, margin and cash-flow improvement, strong clinical catalysts and strategic deals) significantly outweigh the manageable operational and one-time headwinds.View all GB:0HOY earnings summaries0HOY Revenue Breakdown
33.99% MedSurg
66.01% Cardiovascular
0HOY Stock 12 Month Forecast
Average Price Target
$103.00
▲(67.62% Upside)
Technical Analysis
Abbott Laboratories
―
Edwards Lifesciences
―
Medtronic
―
Stryker
―
Zimmer Biomet Holdings
―
Options Prices
Currently, No data available
---